Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model

Cécile Hérate; Romain Marlin; Franck Touret; Nathalie Dereuddre-Bosquet; Flora Donati; Francis Relouzat; Laura Junges; Mathilde Galhaut; Océane Dehan; Quentin Sconosciuti; Antoine Nougairède; Xavier de Lamballerie; Sylvie van der Werf; Roger Le Grand

doi:10.1016/j.heliyon.2023.e16664

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model

Heliyon. 2023 Jun;9(6):e16664. doi: 10.1016/j.heliyon.2023.e16664. Epub 2023 May 30.

Authors

Cécile Hérate¹, Romain Marlin¹, Franck Touret², Nathalie Dereuddre-Bosquet¹, Flora Donati^{3

4}, Francis Relouzat¹, Laura Junges¹, Mathilde Galhaut¹, Océane Dehan^{3

4}, Quentin Sconosciuti¹, Antoine Nougairède², Xavier de Lamballerie², Sylvie van der Werf^{3

4}, Roger Le Grand¹

Affiliations

¹ Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 18 route du Panorama, 92265, Fontenay-aux-Roses, France.
² Unité des Virus Émergents (UVE), Aix Marseille Université, IRD 190, INSERM 1207, 27 Bd Jean Moulin, 13005, Marseille, France.
³ Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Molecular Genetics of RNA Viruses Unit, 25-28 Rue du Dr Roux, 75015, Paris, France.
⁴ Institut Pasteur, Université Paris Cité, National Reference Center for Respiratory Viruses, 25-28 Rue du Dr Roux, 75015, Paris, France.

Abstract

The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could retain partial activity against recent omicron sub-lineage such as BA.5 variants, including BQ.1.1. Here we report full efficacy of Sotrovimab against BQ.1.1 viral replication as measure by RT-qPCR in a non-human primate challengemodel.

Keywords: BQ.1.1; Non human primate; SARS-CoV2; Sotrovimab.